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Abstract
Recent findings suggest that the relaxin-3 neural network may represent a new ascending arousal pathway able to
modulate a range of neural circuits including those affecting circadian rhythm and sleep/wake states, spatial and emotional
memory, motivation and reward, the response to stress, and feeding and metabolism. Therefore, the relaxin-3 receptor
(RXFP3) is a potential therapeutic target for the treatment of various CNS diseases. Here we describe a novel selective RXFP3
receptor positive allosteric modulator (PAM), 3-[3,5-Bis(trifluoromethyl)phenyl]-1-(3,4-dichlorobenzyl)-1-[2-(5-methoxy-1H-
indol-3-yl)ethyl]urea (135PAM1). Calcium mobilization and cAMP accumulation assays in cell lines expressing the cloned
human RXFP3 receptor show the compound does not directly activate RXFP3 receptor but increases functional responses to
amidated relaxin-3 or R3/I5, a chimera of the INSL5 A chain and the Relaxin-3 B chain. 135PAM1 increases calcium
mobilization in the presence of relaxin-3NH2 and R3/I5NH2 with pEC50 values of 6.54 (6.46 to 6.64) and 6.07 (5.94 to 6.20),
respectively. In the cAMP accumulation assay, 135PAM1 inhibits the CRE response to forskolin with a pIC50 of 6.12 (5.98 to
6.27) in the presence of a probe (10 nM) concentration of relaxin-3NH2. 135PAM1 does not compete for binding with the
orthosteric radioligand, [
125I] R3I5 (amide), in membranes prepared from cells expressing the cloned human RXFP3 receptor.
135PAM1 is selective for RXFP3 over RXFP4, which also responds to relaxin-3. However, when using the free acid (native)
form of relaxin-3 or R3/I5, 135PAM1 doesn’t activate RXFP3 indicating that the compound’s effect is probe dependent. Thus
one can exchange the entire A-chain of the probe peptide while retaining PAM activity, but the state of the probe’s c-
terminus is crucial to allosteric activity of the PAM. These data demonstrate the existence of an allosteric site for modulation
of this GPCR as well as the subtlety of changes in probe molecules that can affect allosteric modulation of RXFP3.
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Introduction
RXFP3, also known as GPCR 135 [1] or the SALPR [2], is the
cognate receptor for relaxin-3 (Relaxin-3). Relaxin-3 and related
receptors will be referred to by their IUPHAR terminology [3].
RXFP3 is a class A, Gi/o linked GPCR with an extensive
distribution in the central nervous system (CNS), particularly in
areas involved in memory, sensory and emotional processing [4].
The CNS distribution of RXFP3 is conserved in mice and
macaques [5,6]. RXFP4, the INSL5 receptor, is the closest
homolog to RXFP3 [7].
Relaxin-3 is a member of the insulin superfamily, which
includes insulin, insulin-like growth factor, the relaxin hormone
(H1/H2 Relaxin) and insulin-like peptides (INSL-3, 4, 5 and 6). In
addition to RXFP3, relaxin-3 is capable of high affinity interaction
with RXFP4. However, RXFP4 and its native ligand (INSL5) are
thought to be more active in the periphery [7]. RXFP4 is a
pseudogene in the rat [8] and does not appear to be expressed in
the mouse brain [9]. While Relaxin-3 shares part of its name with
H1/H2 Relaxin, it has a distinct distribution and roles compared
to the hormonal H1/H2 Relaxin. H1/H2 Relaxin acts through
RXFP1 [10] and has important roles in collagen remodeling,
impacting diverse physiological processes from pregnancy [11] to
asthma [12] and heart failure [13]. Relaxin-3 is highly and focally
expressed in the nucleus incertus of the hind brain of the mouse
[6,14], rat [1], and an equivalent area of the macaque [5]. Apart
from the Relaxin-3 distribution, behavioral data suggest that
Relaxin-3 has a role in stress/anxiety [15], cognition [16] and
appetite regulation [17,18]. The tissue distribution and function of
Relaxin-3 and RXFP3 indicate potential therapeutic application
of RXFP3 modulators to treat stress/anxiety, cognitive disorders
and metabolic diseases [19]. In vivo agonist stimulation of RXFP3
in rodents increases hippocampal theta emissions and improves
performance in behavioral cognitive assays [16,20].
Selective orthosteric, high affinity agonist (R3/I5) and antago-
nist (R3(D23–27)R/I5) peptides have been discovered for RXFP3
[21,22]. The selective agonist (R3/I5) pairs the INSL-5 A chain
with Relaxin-3’s B chain, yielding a selective, high affinity, full
RXFP3/4 agonist. Residues 23 through 27 of the Relaxin-3 B
chain are necessary for agonist activity and removing those resides
from R3/I5 creates a competitive antagonist (R3(D23–27)R/I5).
While these peptide modulators of RXFP3/4 have been useful,
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receptors have yet to be described in the literature.
GPCR agonists and antagonists can act either orthosterically, at
the same site as the native agonist, or allosterically at a separate
site on the receptor. Positive allosteric activity can take the form of
allosteric agonism (activity in the absence of an orthosteric agonist)
or positive allosteric modulation (PAM; requires presence of an
orthosteric agonist) [23,24,25]. Positive allosteric modulators have
several theoretical advantages over direct agonists as therapeutic
agents. As PAM compounds modify the efficacy of an orthosteric
agonist and lack activity on their own, these compounds are
expected to have an effect only in tissues where and when the
endogenous agonist is released. The ability of PAM compounds to
exhibit biological activity in a regulated manner enhances their
safety profile and makes them attractive tools over traditional
therapeutic agents [26].
In the case of positive allosteric modulation, the allosteric
activity is measured in the presence of an orthosteric agonist,
referred to as a probe. Examples of PAM compounds with probe-
specific activities have been described in the literature [27]. Here
we describe a RXFP3 PAM compound (135PAM1, Figure 1)
which is a striking example of probe selectivity. In this case, one
can exchange the entire A-chain of the probe peptide while
retaining PAM activity, but the state of the probe’s c-terminus is
crucial to allosteric activity of the PAM.
Materials and Methods
Materials
All cell culture supplies, Fluo-3 AM calcium dye and Pluronic
acid F-127 were obtained from Invitrogen (Carlsbad, CA).
Probenecid and forskolin were obtained from Sigma (St. Louis,
MO). Chlorophenol red-b-D-galactopyranoside (CPRG) was
purchased from Roche Applied Science (Indianapolis, IN). C-
terminally amidated Relaxin-3 (relaxin-3NH2) and R3/I5 (R3/
I5NH2) were obtained from Dr. John Wade at the Howard Florey
Institute (Melbourne, Australia). The C-terminal free acid forms of
Relaxin-3 and R3/I5 were purchased from Peprotech (Rocky Hill,
NJ) and Phoenix Pharmaceuticals (Burlingame, CA), respectively.
For these studies both the A and B chains of the peptide were
amidated (i.e. Relaxin-3NH2) or left in the free acid form (i.e.
Relaxin-3OH). Amidated R3/I5 (R3/I5NH2) was radioiodinated
with Na
125I using the chloramine T methodology as previously
described [28]. 135PAM1 (3-[3,5-Bis(trifluoromethyl)phenyl]-
1-(3,4-dichlorobenzyl)-1-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea)
was synthesized and prepared at Johnson & Johnson Pharma-
ceutical Research and Development, L.L.C.
Cell Lines
Stable cell lines expressing RXFP3 and RXFP4 were created as
previously described [1,8,29]. Clonal, stable cell lines were made
using the receptor genes of interest, cloned into pCIneo (Promega,
Madison, WI). For functional assays measuring inhibition of the
cAMP pathway, the receptor constructs were transfected into SK-
N-MC cells (ATCC, Manassas, VA) expressing a CRE reporter
linked to b-galactosidase expression. Other assays were performed
using stable clones of HEK-293 cells (ATCC, Manassas, VA)
coexpressing the receptor gene of interest (RXFP3 or RXFP4) and
chimeric Ga protein GqI5 [30].
Ca
2+ Mobilization Assay
Intracellular Ca
2+assays were used to assess the effect of
135PAM1 to either increase the response to a probe quantity of
an agonist (,EC20) or to measure changes in an agonist’s EC50 at
various compound doses. In either case, adherent HEK-293 cells
expressing GqI5 were grown to confluency in DMEM media
supplemented with 10% fetal bovine serum, 50 iu/ml penicillin,
50 mg/ml streptomycin, 1 mM Na Pyruvate, 10 mM HEPES, and
600 mg/ml G418. On the day before the assay the cells were
detached with 10 mM trypsin/EDTA and seeded on black poly-
D-lysine-coated 96-well plates (BD Bioscience, San Jose, CA) at a
density of 35,000 cells/well, then incubated overnight at 37uC, 5%
CO2. On the next day, the culture medium was discarded and
replaced with a calcium dye solution, containing 4 mM Fluo-3
(AM), 2.5 mM probenecid and 0.04% Pluronic acid F-127 in
DM:F12 medium. Cells were incubated in the dye solution for
60 min at room temperature or 30 min at 37uC. Ligand-
stimulated Ca
2+ mobilization was monitored using FLIPR Tetra
High Throughput Cellular Screening System (Molecular Devices,
Sunnyvale, CA).
An initial assay assessed the effect of 135PAM1 to increase the
effect of an EC20 dose of Relaxin-3 or R3/I5 (each as the c-
terminal acid or amide). In this case, the cells were incubated with
a dose-response of 135PAM1 (0 to 20 mM) for 10 min at room
temperature, then Relaxin-3 or R3/I5 was added by the FLIPR
Tetra (Molecular Devices, Sunnyvale, CA) as Ca
2+responses were
recorded.
Shifts in the dose response curve of the orthosteric agonist were
assayed using the HEK-293 cell lines co-expressing GqI5. In this
case, the cells were incubated with 135PAM1 at 0, 0.2, 2 and
20 mM for 10 min at room temperature. The FLIPR Tetra then
added full dose-response curves of the orthosteric agonist (H3
relaxin or R3/I5; 0 to 200 nM) at each concentration of
135PAM1 while recording data.
Results of 3 or more triplicate assays were plotted and
calculated using GraphPad Prism version 5.03 (GraphPad, La
Jolla, CA). The allosteric site Kb was calculated from agonist curve
shift assays using the Christopoulos/Kenakin equation [23]. This
calculation accounts for the limiting character of the shift in the
orthosteric agonist’s EC50 due to allosteric modulation. Results
were analyzed together after normalization and are reported with
confidence intervals in parenthesis.
cAMP Reporter Assay
Alterations in cAMP response element (CRE) activity were used
to assess the functional effects of peptide agonists and 135PAM1
using methods previously described [1,8,29]. For these assays,
stable clones of SK-N-MC cells (ATCC, Manassas, VA) were
selected to express the receptor of interest (RXFP3 or RXFP4)
Figure 1. Structure of 135PAM1 (3-[3,5-Bis(trifluoromethyl)-
phenyl]-1-(3,4-dichlorobenzyl)-1-[2-(5-methoxy-1H-indol-3-
yl)ethyl]urea).
doi:10.1371/journal.pone.0030792.g001
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expression. CRE activity was stimulated with forskolin in cells
expressing RXFP3 or RXFP4 and then inhibition of the CRE
activity by agonist was tested with and without 135PAM1. In this
reporter assay CRE activity is reflected in b-galactosidase
expression. After incubations with compound and/or peptide
agonist for 6 hours at 37 C the medium on the cells was discarded.
The cells were then lysed and the assay was developed as
previously described using the colored substrate chlorophenol red-
b-D-galactopyranoside (CPRG) [1].
As described above for Ca
2+ assays, CRE activity was measured
to assess dose related effects of 135PAM1 on peptide agonists at
probe concentrations (EC20) and to assay 135PAM1-dependent
shifting of the agonist dose response curves. In both cases the cells
were grown in MEM supplemented with 10% fetal bovine serum,
50 iu/ml penicillin, 50 mg/ml streptomycin, 2 mM L-Glutamine,
16 MEM Non-Essential Amino Acids (Gibco/InVitrogen,
Carlsbad, CA), 1 mM Sodium Pyruvate, and 600 mg/ml G418.
At confluency, the cells were detached and seeded in 96-well plates
at a cell density of 50,000 cells/well for incubation overnight at
37uC, 5% CO2. On the following day, the media was discarded
and cells were pre-incubated with 135PAM1 at the indicated
concentration for 10 min at room temperature. Immediately
thereafter, relaxin3 or R3/I5 was added as indicated and
incubated for 10 min at room temperature. The cells were then
stimulated with forskolin (5 mM, final concentration) and incubat-
ed at 37uC, 5% CO2 for 6 hours. Following washes with assay
buffer, the cells were lysed and b-galactosidase activity was
visualized by incubation with CPRG for up to 30 min at room
temperature and absorbance was read at 570 nm. Results of 3 or
more triplicate functional assays were analyzed together after
normalization by non-linear regression (Prism, GraphPad, San
Diego, CA) and are reported with confidence intervals in
parenthesis.
Radioligand Receptor Binding Assay
Membrane homogenates were prepared from confluent 15 cm
tissue culture dishes of HEK-293 cells expressing GqI5 (see above
for Ca
2+ functional assays). Cells were removed from the tissue
culture dishes with DPBS+5 mM EDTA (pH 7.4), then centri-
fuged and stored at 280 C. On the day of the assay 14 ml of
homogenization buffer (50 mM Tris HCl+5 mM EDTA
pH 7.5+Complete Protease Inhibitor cocktail (Roche, South San
Francisco, CA) was added to the cell pellet, which was then
homogenized for 15 seconds using a Handishear homogenizer
(Virtis). The homogenate was spun at 500 xg for 5 minutes at 4 C,
then the supernatant fraction was spun at 27000 xg for 30 minutes
at 4 C. The resulting membrane pellet was resuspended in 16 ml
of homogenization buffer with Compete Protease Inhibitors,
briefly homogenized using the Handishear (Virtis), and then kept
on wet ice.
Membrane homogenates were used to measure homologous or
heterologous binding displacement of [
125I]R3I5NH2. Peptides and
tracer were diluted in assay buffer (50 mM Tris HCl+5m M
EDTA pH 7.5) with 0.5% BSA added. Reactions were set up in a
total volume of 100 ml. The PAM compound was diluted in 50 C
assay buffer as a 56concentrate and added to the binding reaction
promptly to avoid precipitation. [
125I]R3I5(amide) was added to a
net concentration of 14 pM. Binding reactions were incubated for
90 minutes at room temperature, then filtered through GF/C
membranes pretreated with polyethyleneimine using a 96 well
Brandel apparatus (Brandel, Gaithersberg, MD). The filter plates
were dried, then Microscint (Perkin Elmer, Shelton, CT) was
added and the plates were counted on a Top Count (Perkin Elmer,
Shelton, CT). Data were evaluated using GraphPad Prism 5.01
(GraphPad Software, San Diego, CA). Results of 3 or more
triplicate functional assays were analyzed by non-linear regression
(GraphPad Prism). Results were analyzed together after normal-
ization and are reported with confidence intervals in parenthesis.
Calculation of a cooperativity value between 135PAM and the
radioligand peptide was calculated using the allosteric modulator
equation based on the ternary complex model in GraphPad Prism.
Results
135PAM1 is a RXFP3 positive allosteric modulator with
unique probe dependence
135PAM1’s positive allosteric activity was demonstrated in
functional assays using probe quantities of the orthosteric agonists
and in dose response assays showing shifts in orthosteric agonist
pEC50 values with increasing quantities of compound. Functional
positive allosteric activity was retained following substitution of the
entire A-chain of relaxin-3 (e.g. R3/I5NH2), however c-terminal
amidation of the RXFP3 orthosteric agonist peptide was required
for PAM activity of 135PAM1.
First, ascending doses of 135PAM1 were shown to increase
calcium mobilization elicited by a probe concentration of Relaxin-
3 (amide or free-acid) or R3I5 (amide or free-acid) (Figure 2).
HEK293 cells co-expressing RXFP3 and Gqi5 were incubated with
increasing concentrations of 135PAM1, followed by addition of
relaxin-3 or R3/I5 at the EC20 (the EC20 was determined using a
separate plate on the day of the assay). 135PAM1 potentiated the
RXFP3-mediated calcium response to amidated relaxin-3 and
R3/I5 (Fig. 2 A and C), but not to free acid analogs of either
peptide (Fig. 2 B and D). As shown in Fig. 2A, 135PAM1 lacked
agonist activity in the absence of a RXFP3 orthosteric agonist.
135PAM1 was more potent at RXFP3 in the presence of relaxin-
3NH2 (pEC50 6.55 [6.46 to 6.64]) than R3/I5NH2 (pEC50 6.07
[5.94 to 6.20]). The EMax of 135PAM1 in the presence of Relaxin-
3NH2 at its EC20 was significantly less than the EMax of the pep-
tide (P,0.01; Relaxin-3NH2 EMax=25811 AU [24571–27051],
135PAM1 EMax with probe=22362 AU [21642–25221]). Simi-
larly, the EMax of 135PAM1 with R3/I5NH2 at its EC20 was
significantly less than the EMax of R3/I5NH2 (P,0.03; R3/I5NH2
EMax=23086 AU [22257–23914], 135PAM1 EMax with
probe=21194 AU [19389–22999].
135PAM1 also shifted the relaxin-3NH2 and R3I5NH2 concen-
tration-response curves in a limiting manner that is indicative of
allosteric activity (Figure 3). For these experiments, cells from the
same clone of HEK-293 cells expressing RXFP3 and GqI5 were
preincubated with fixed concentrations of 135PAM1 (0, 0.2, 2.0,
20 mM) and then stimulated with increasing concentrations of
relaxin-3NH2 or R3/I5NH2. 135PAM1 elicited a similar dose-
dependent leftward shift in the relaxin-3NH2 (1.4–2.3 fold) and
R3/I5NH2 (1.3–2.6 fold) concentration-response curves (Fig. 3 A
and B), but did not significantly shift free agonist peptide dose
response curves (Fig. 3C and 3D). An allosteric ternary complex
model estimated the RXFP3 pKb value of 135PAM1 to be 6.45
(6.16 to 6.74) using the relaxin-3NH2 probe or 6.02 (5.87 to 6.18)
for the R3/I5NH2 probe.
RXFP3 is a Gi/o linked GPCR [31,32], therefore a cAMP
response element (CRE) reporter assay was used to confirm the
positive allosteric modulator activity of 135PAM1 in bioassays
avoiding use of a chimeric G-protein. Results of these studies were
consistent with those obtained above using GqI5.
Similar to the Ca
2+ mobilization assays described above, CRE
activity was first evaluated using escalating concentrations of
135PAM1 and probe concentrations of relaxin-3. When added to
Positive Allosteric Modulator of RXFP3
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5 mM forskolin with a pIC50 of 6.12 (5.98 to 6.27), but had no
effect on the CRE response to Relaxin-3OH (see Fig. 4 A and C).
The EMax observed for inhibition of the CRE response to 5 mM
forskolin by 135PAM1 at 30 mM was less than the EMax of
Relaxin-3NH2, however the dose response curve had not yet
reached its asymptote and testing of 135PAM1 at a higher
concentration was not possible due to solubility limitations
(Fig. 4A). While calculation of the 135PAM1 EMax is impractical
in this case, the results are similar to those observed above for Ca
2+
measurements in HEK293 cells co-expressing RXFP3 and Gqi5.
135PAM1 also shifted Relaxin-3NH2 (Fig. 5A) and R3/I5NH2
(Fig. 5B) inhibition of forskolin-stimulated CRE responses to the
left, increasing the efficacy of these peptide agonists. An allosteric
ternary complex model estimated the RXFP3 pKb value of
135PAM1 to be 5.59 (5.37 to 5.80) when shifting the relaxin-3NH2
curve or 5.05 (4.70 to 5.40) when shifting the R3/I5NH2 curve.
135PAM1 has no affinity at the orthosteric binding site of
the RXFP3 receptor
We assessed the ability of 135PAM1 to compete for binding
with the orthosteric radioligand, [
125I] R3I5 (amide), at the
orthosteric site using membranes prepared from RXFP3-
HEK293-Gqi5 cells (Fig. 6). 135PAM1 failed to displace 14 pM
[
125I] R3I5 (amide) at concentrations of up to 20 mM (Fig. 6). In
contrast, the orthosteric agonist, R3I5 (amide), displaced [
125I]
R3I5 (amide) with a pIC50 of 8.76 (8.61 to 8.91) (Fig. 6). At higher
concentrations of 135PAM1 an increase in binding was observed,
consistent with positive allosterism [33]. Further calculation of
these data for 135PAM1 showed positive cooperativity with an a
of 1.4 [23].
135PAM1 is selective for RXFP3
Receptor selectivity of 135PAM1 was explored using RXFP4,
which has the highest known sequence identity (43%) compared to
RXFP3 [29]. Relaxin-3 and R3/I5 are full RXFP4 agonists.
While Relaxin-3 in either the free acid or c-terminally amidated
forms inhibited the CRE response to 5 mM forskolin in cells
expressing RXFP4, 135PAM1 (at up to 20 mM) had no effect on
either analog of relaxin-3 at EC20 concentrations (Fig. 4B and 4D).
Ancillary pharmacology was further evaluated using broad
profiling screen at CEREP and in house, evaluating a total of 60
GPCRs, ion channels and transporters in radioligand binding
assays, resulted in only four significant activities (dopamine
Figure 2. 135PAM1 increases the intracellular Ca
2+ response to amidated, but not free acid RXFP3 agonists in cells coexpressing
RXFP3 and GqI5. Intracellular Ca
2+ responses by HEK-293 cells coexpressing RXFP3 and GqI5 were measured in response to escalating concentrations
of 135PAM1 using probe (EC20) concentrations of Relaxin-3NH2 (A), Relaxin-3OH (B), R3/I5NH2 (C), or R3/I5OH (D).
doi:10.1371/journal.pone.0030792.g002
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10 mM, serotonin 5-HT1A 74% at 10 mM and sodium channel
site 2 83% inhibition at 10 mM). In addition, the compound was
tested against OX2R and NPSR in an in vitro functional assay
(FLIPR). In these 2 assays, when incubated in the presence of
EC20 concentrations of either orexin A or NPS, 135PAM1 did not
show any PAM activity at concentrations up to 20 mM.
Discussion
Neuropeptides have long been recognized to have therapeutic
potential. Successful uses of peptides have been primarily in
peripheral applications, for example, in the tachykinin, somato-
statin, angiotensin, calcitonin gene-related peptide (CGRP),
orexin, or glucagon-like peptide1 fields [34]. Manipulation of
native peptide agonists to take advantage of key domains has
yielded receptor antagonists such as a-helical CRF(9–41) [35] and
R3(D23–27)R/I5 [21]. R3/I5, the RXFP3/4 agonist used in these
studies, was similarly constructed to retain the domain needed for
RXFP3/4 activity while eliminating the domain needed for
RXFP1/2 activity [22]. Given the complex nature of receptor–
ligand interactions at the orthosteric site of GPCRs, it is not
surprising that the number of such ligands, especially brain
penetrant agonists, is very limited. Many synthetic neuropeptide
analogs exist, but most of them are peptides, with inherent
limitations (i.e. bioavailability, stability, brain penetration). In the
last decade, allosteric modulation of GPCRs has offered great
opportunities for receptors for which the chemical space is limited.
Negative allosteric modulators of CRF, CGRP, GLP1 or ghrelin
receptors have been discovered [36]. When it comes to agonists,
almost no neuropeptide receptor PAMs are described. L-692,429,
a ghrelin receptor PAM, is one of the very few peptide receptor
PAMs to be described [37]. Additionally, low molecular weight
ago-allosteric compounds acting on GLP1 receptors exist [38].
Recent data point to the therapeutic potential of an RXFP3
agonist or positive modulator [39], however, selective, systemically
active, nonpeptide relaxin-3 receptor ligands have not yet been
discovered [39]. Here, we describe the in vitro characterization of
the first RXFP3 receptor PAM, 135PAM1. 135PAM1 was
discovered in an antagonist screen of more than 100,000
compounds when negative inhibition of R3/I5NH2 activity on
RXFP3 was noticed. Approximately 0.1% of the compounds
tested in the screen displayed the negative inhibition and
135PAM1 proved to be a selective RXFP3 positive allosteric
modulator. This low-molecular-weight ligand moderately poten-
tiates the functional responses of amidated Relaxin-3 or amidated
R3/I5 in calcium mobilization and cAMP assays in cell lines
expressing the cloned human RXFP3 receptor. 135PAM1 does
not compete for binding with orthosteric radioligand [
125I]R3/
I5NH2 but instead increases its binding and shows positive
Figure 3. 135PAM1 shifts the concentration response curves of Relaxin-3NH2 and R3/I5NH2. HEK-293 cells coexpressing RXFP3 and GqI5
were incubated with fixed concentrations of 135PAM1 (0, 0.2, 2 and 20 mM) 10 min before the addition of increasing concentrations of Relaxin-3NH2
(A), R3I5NH2 (B), Relaxin-3OH (C) or R3I5OH (D).
doi:10.1371/journal.pone.0030792.g003
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lacks similar activities when using the free acid form of relaxin-3
(the native form) or R3/I5 instead of the amidated form,
indicating that the compound is subject to probe dependency
related to the state of the probe’s c-terminus. This compound
demonstrates a site for allosteric modulation of RXFP3 and shows
the importance of following such compounds using a free acid
probe.
Positive allosteric modulation of RXFP3 by 135PAM1 has been
shown using a chimeric GqI5 protein to shift signaling to
intracellular Ca
2+ and in assays measuring native Gi/o signaling.
When given with probe concentrations of Relaxin-3NH2 or R3/
I5NH2, 135PAM1 has an Emax slightly lower than either peptide
(fig. 2A, 2C and 4A). The PAM compound shifts the concentration
response of either amidated agonist peptide in a dose related
fashion (fig. 3 and 5). The apparent pKb for the allosteric site is
higher when using the Gqi5-linked functional assay (pKb=6.45 for
the relaxin-3NH2 shift; Fig. 3A) than in the native Gi/o-linked assay
(pKb=5.6 for the relaxin-3NH2shift; Fig. 5A). The pKb is high
enough in the Gqi5-linked functional assay to show saturation of
the PAM effect (Fig. 3A/B), however the limited solubility of
135PAM1 makes it impractical to demonstrate saturability of that
effect in the native Gi/o-linked assay (Fig. 5A).
In addition to the Ca
2+ mobilization assay, we utilized a CRE
reporter assay to evaluate the pharmacology of the RXFP3
positive allosteric modulator, 135PAM1. RXFP3 is functionally
coupled to the inhibition of cAMP through the inhibition of
adenylate cyclase when coupling to Gi/o proteins. We observed
that increasing concentrations of both Relaxin-3NH2 and R3I5NH2
inhibit CRE activation and that 135PAM1 potentiates this effect.
However, CRE can be transactivated by multiple signaling
pathways, including cAMP and ERK [40]. Van der Westhuizen
et al demonstrated that Relaxin-3 induces ERK1/2 phosphory-
lation via activation of Gi/o proteins [41]. Taking this into
consideration, Relaxin-3 and related peptides could induce the
activation of the CRE response in our assay via ERK1/2.
However, since the van der Westhuizen’s group reported
maximum P-ERK1/2 levels for just minutes following Relaxin-3
administration and our CRE reporter assay incubates for 6 hours
at 37 C, we speculate any effect of ERK signaling observed was
minimal.
The lack of affinity of 135PAM1 for the orthosteric site of
RXFP3 and the lack of effect of 135PAM1 on baseline cAMP or
calcium suggests 135PAM1 is a positive allosteric modulator of
RXFP3 without intrinsic activity. Also, receptor selectivity of
135PAM1 at RXFP3 has been demonstrated by comparison with
cells expressing RXFP4, a GPCR with high homology to RXFP3
[29]. The selectivity of the effect of 135PAM1 at RXFP3 was
evidenced by its lack of effect on Relaxin-3 or R3/I5 (amidated or
free acid) responses in cells stably expressing RXFP4 receptors
Figure 4. 135PAM1 dose-dependently augments the inhibition of CRE activity of probe (EC20) concentrations of Relaxin-3NH2 in
cells expressing RXFP3, but not RXFP4. As RXFP3 and RXFP4 are Gi/o-linked receptors, experiments analogous to Fig. 2 were performed without
the use of a chimeric G protein, comparing cAMP response element (CRE) activity in cells expressing RXFP3 (panels A and C) to closely related
receptor RXFP4 (panels B and D). RXFP3 or RXFP4 receptors were expressed in SK-N-MC cells co-expressing a CRE construct linked to b-galactosidase
expression. Forskolin (5 mM) was used to stimulate CRE activity and ascending doses of 135PAM1 were added to probe (EC20) concentrations of
Relaxin-3NH2 (A and B) or Relaxin-3OH (C and D).
doi:10.1371/journal.pone.0030792.g004
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activity against 60 other receptors and channels, with no
remarkable activity reported.
Initial studies demonstrated that the amidated and free-acid
forms of Relaxin-3 were equipotent [42]. However, recent results
both here and elsewhere (Ross Bathgate, personal communication)
have shown amidated RXFP3 agonists (Relaxin-3 and R3/I5) to
be roughly 10 fold less efficacious (lower pEC50) than their free
acid analogs. Early work with native free acids of these insulin-like
peptides used recombinant material made in eukaryotic cells,
which was purified to homogeneity [1,22]. Insulin-like peptides
have since become synthetically tractable [43] and such methods
have allowed for modifications such as c-terminal amidation of the
peptide chains. 135PAM1 was discovered using amidated peptide,
as amidation of peptides tends to increase solubility, increase
stability and prior data indicated amidation of RXFP3 agonists did
not alter potency [42]. All materials described here were made
synthetically and were checked by LCMS. Molecular masses were
correct and consistent with both chains of both peptides being free
acids or amidated, as indicated. The reason for the observed
differential potencies of c-terminal amides versus acid peptides
remains unclear.
While allosteric modulators with probe dependency have been
described in the literature [27,44,45], 135PAM1 is a unique
example. Allosteric activity is retained while substituting the entire
A-chain of Relaxin-3NH2 with the A-chain of INSL-5NH2 (yielding
R3/I5NH2), yet 135PAM1 is inactive when the native free acid
forms of these peptides are used as probes. Perhaps the most cited
examples of probe dependent allosteric modulators are for M4
acetylcholine receptors [45,46] and the CCR5 chemokine receptor
[47]. In the case of the M4 receptor, LY2033298 shows greater
cooperativity with oxotremorine than with acetylcholine or
xanomeline. Oxotremorine, acetylcholine and xanomeline are
small molecules with substantial chemical differences. In the
chemokine receptor example, 873140 shows probe dependent
allosteric antagonism at CCR5 using a site common to four other
known inhibitors [47]. However, the various endogenous ligands
used as probes for chemokine receptors such as CCR5 are
peptides with substantial sequence variability [48]. In either case
the probe agonists for the receptor in question are far more
variable than the differential c-terminal amidation shown here.
Probe selective allosteric modulators of the GLP-1 receptor are
in some ways comparable to the probe dependence described
here. Structurally similar flavonoids show positive cooperativity
with GLP-1 fragments and exendin-4, but not oxyntomodulin
[49]. A hydroxyl group is crucial to positive cooperativity, but this
differs from the RXFP3 case in that the needed hydroxyl group is
on the allosteric modulator, as opposed to the probe.
Here, we have shown the free acid and amide forms of Relaxin-3
display different potencies at the RXFP3 receptor and described
135PAM1, a novel positive allosteric modulator of RXFP3. This
RXFP3 PAM is selective to RXFP3 over RXFP4 and a panel of
other receptors, shows activity in assays measuring GqI5-linked
changes in intracellular Ca
2+ or native Gi/o linked cAMP, and
shows probe selectivity. 135PAM1 shows a probe selectivity
dependent on the c-terminal amidation state of the peptide agonists,
unfortunately favoring c-terminal amides which have not been
shown to occur in nature. 135PAM1 is the first publicly disclosed
positive allosteric modulator of RXFP3. Since 135PAM1 lacks
activity when used with the native, free acid form of relaxin3 and
has severe solubility limitations, the compound has very limited
utility. 135PAM1 would lack in vivo activity when given alone, but
could be used to potentiate effects of exogenous Relaxin-3NH2 or
R3/I5NH2. This example demonstrates the subtlety of differences in
probe agonists which can lead to probe dependence.
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